Cargando…
Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy
BACKGROUND: Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study partners, compared to participants themselves, provide added information about...
Autores principales: | Ryan, Mary M., Grill, Joshua D., Gillen, Daniel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800492/ https://www.ncbi.nlm.nih.gov/pubmed/31627738 http://dx.doi.org/10.1186/s13195-019-0539-3 |
Ejemplares similares
-
Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials
por: Nuño, Michelle M., et al.
Publicado: (2019) -
Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
por: Bernstein, Olivia M., et al.
Publicado: (2021) -
Study partners should be required in preclinical Alzheimer’s disease trials
por: Grill, Joshua D., et al.
Publicado: (2017) -
Study partners: essential collaborators in discovering treatments for Alzheimer’s disease
por: Largent, Emily A., et al.
Publicado: (2018) -
Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms
por: Munro, Catherine E., et al.
Publicado: (2022)